AbbVie's second quarter of fiscal 2026 marked a decisive inflection in the company's post-Humira transition. Worldwide net revenues rose 11 percent on a reported basis to $32.0 billion for the first half of the year, with the immunology franchise delivering 24 percent constant-currency growth from Skyrizi and Rinvoq combined. That growth more than offset the 38 percent decline in Humira revenues, which fell to $3.7 billion for the six-month period as biosimilar competition accelerated following the loss of U.S. exclusivity. Operating earnings climbed to $10.4 billion and diluted earnings per share reached $2.42 for the first half, while cash flows from operations generated $7.3 billion. The quarter demonstrated that the revenue base has diversified sufficiently to absorb the Humira cliff while funding continued pipeline investment and shareholder returns.
The investment thesis rests on three variables with distinct market tracking signals. First, the immunology growth trajectory: Skyrizi and Rinvoq need to sustain mid-20s percentage growth to replace Humira's lost revenue within the next eighteen to twenty-four months, with the market watching quarterly constant-currency growth rates and new indication approvals as confirmation. Second, the neuroscience franchise durability: Vraylar, Ubrelvy, Qulipta, and the newly launched Vyalev collectively grew in the high teens to low 30s, and their ability to maintain momentum against generic and competitive pressures determine whether neuroscience becomes a second pillar of sustainable growth. Third, the contingent consideration liability overhang: the $3.9 billion fair value increase in the first half reflects rising Skyrizi sales expectations and pipeline optionality, but the non-cash volatility creates earnings opacity that the market discount until the Skyrizi royalty stream matures and pipeline milestones resolve.
The binary market implications center on whether the immunology franchise can achieve $30 billion in combined peak sales. Confirmation arrives if Skyrizi and Rinvoq sustain 20 percent-plus growth through 2027 with at least two major label expansions each, driving the multiple toward the large-cap biopharma peer median of 14 to 15 times forward earnings. The thesis breaks if immunology growth decelerates to low teens before Humira stabilizes, or if the IRA Medicare price negotiation on Botox expands to Skyrizi or Rinvoq in the 2027 guidance cycle, which would compress the multiple toward 10 to 11 times. The Apogee Therapeutics acquisition, pending closure, adds a fourth variable: successful integration of the ADORA2a antagonist program could open the atopic dermatitis market, but a failed Phase 3 readout would impair the $10 billion term loan capacity and signal pipeline execution risk.